Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.88 USD
Change Today -0.09 / -3.03%
Volume 785.2K
As of 8:10 PM 04/1/15 All times are local (Market data is delayed by at least 15 minutes).

invivo therapeutics holdings (NVIV) Snapshot

Open
$2.97
Previous Close
$2.97
Day High
$2.99
Day Low
$2.80
52 Week High
03/3/15 - $3.12
52 Week Low
09/10/14 - $0.47
Market Cap
294.9M
Average Volume 10 Days
957.2K
EPS TTM
$-0.18
Shares Outstanding
102.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INVIVO THERAPEUTICS HOLDINGS (NVIV)

Related News

No related news articles were found.

invivo therapeutics holdings (NVIV) Related Businessweek News

No Related Businessweek News Found

invivo therapeutics holdings (NVIV) Details

Invivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, focuses on developing and commercializing technologies for the treatment of spinal cord injury (SCI). The company is developing a Neuro-Spinal Scaffold, an investigational bioresorbable polymer scaffold for the implantation at the site of injury within a spinal cord contusion; and biocompatible Neuro-Spinal Scaffold Plus Stem Cells to treat chronic SCI. Its proprietary technologies incorporate intellectual property licensed under exclusive, worldwide license from Boston Children's Hospital and the Massachusetts Institute of Technology, as well as intellectual property that has been developed internally in collaboration with advisors and partners. The company was founded in 2005 and is based in Cambridge, Massachusetts.

31 Employees
Last Reported Date: 03/11/15
Founded in 2005

invivo therapeutics holdings (NVIV) Top Compensated Officers

Chief Financial Officer
Total Annual Compensation: $1.0K
Compensation as of Fiscal Year 2013.

invivo therapeutics holdings (NVIV) Key Developments

InVivo Therapeutics Holdings Corp. Announces Amendments to Articles of Incorporation

InVivo Therapeutics Holdings Corp. announced amendments to the Articles of Incorporation.

InVivo Therapeutics Holdings Corp. Reports Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

InVivo Therapeutics Holdings Corp. reported consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported adjusted net loss of $3,876,000 or $0.04 per diluted share compared to $5,707,000 or $0.07 per diluted share a year ago. Net loss was $8,384,000 or $0.09 per diluted share compared to $5,707,000 or $0.07 per diluted share a year ago. For the year, the company reported a net loss of $18,346,000 or $0.21 per basic and diluted share compared to $38,756,000 or $0.52 per basic and diluted share for the year ended December 31, 2013. Operating loss was $17,839,000 against $19,005,000 a year ago. Interest income was $5,000 compared to $15,000 a year ago. Adjusted net loss was $17,661,000 or $0.20 per diluted share compared to $19,120,000 or $0.26 per diluted share for the year ended December 31, 2013.

InVivo Therapeutics Holdings Corp. Announces Froedtert & the Medical College of Wisconsin as New Clinical Trial Site for Neuro-Spinal Scaffold

InVivo Therapeutics Holdings Corp. announced that Froedtert & the Medical College of Wisconsin (MCW) Froedtert Hospital in Milwaukee, WI has been added as a clinical site in the company’s ongoing IDE pilot study of its Neuro-Spinal Scaffold in patients with acute spinal cord injury (SCI). Froedtert Hospital houses the only adult Level 1 trauma center in eastern Wisconsin and receives referred spinal cord injury patients from Wisconsin, northern Illinois, and northern Michigan. Shekar Kurpad, MD, PhD, professor of neurosurgery at MCW and director of the Spinal Cord Injury Center and Spine Surgery Fellowship at Froedtert Hospital, has been named Principal Investigator at the site. On January 22, 2015, InVivo announced enrollment of its second patient in the study at its clinical site, Carolinas Medical Center in Charlotte, NC. InVivo’s patient was enrolled in October 2014 at the Barrow Neurological Institute at St. Joseph’s Hospital and Medical Center in Phoenix, AZ. This is the company’s first clinical study of its investigational degradable polymer Neuro-Spinal Scaffold. The IDE pilot study has been approved by the U.S. Food and Drug Administration (FDA) and is intended to capture preliminary safety and effectiveness data of the Neuro-Spinal Scaffold in five subjects with acute thoracic spinal cord injury. InVivo then expects to conduct a pivotal study to obtain FDA approval to commence commercialization under a Humanitarian Device Exemption (HDE).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVIV:US $2.88 USD -0.09

NVIV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NVIV.
View Industry Companies
 

Industry Analysis

NVIV

Industry Average

Valuation NVIV Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INVIVO THERAPEUTICS HOLDINGS, please visit www.invivotherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.